Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- UCLA Jonsson Comprehensive Cancer Center
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intravenous, Subcutaneous, Intradermal, Intranodal
01
Overview
A personalized, investigational cancer immunotherapy composed of a patient's own (autologous) dendritic cells that have been pulsed ex vivo with a synthetic peptide derived from the NY‑ESO‑1 tumor-associated antigen (specifically amino acids 157–165). NY‑ESO‑1 is a cancer-testis antigen expressed in various tumors and minimally in normal tissues except for testes. The therapy aims to stimulate an immune response—primarily cytotoxic T lymphocyte activation—against NY‑ESO‑1-expressing tumor cells. This approach is being studied mainly for malignant solid tumors and cancers, including sarcoma and neuroblastoma, with clinical trials reaching up to phase 2[2][3][8]. The mechanism involves enhanced presentation of the NY‑ESO‑1 epitope by patient-derived dendritic cells to T-cells, promoting targeted anti-tumor immunity.
- Other names
- ny-eso-1(157–165) peptide-pulsed dc vaccineny-eso-1(157–165)-pulsed dendritic cell vaccineny‑eso‑1 157–165 peptide pulsed dendritic cells
02
Targets
pMHC-I (Peptide–MHC class I complex)HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NY-ESO-1(157-165) peptide-pulsed autologous dendritic cell vaccine.